Perimeter Schedules First Quarter 2026 Financial Results Conference Call for May 28th
Perimeter Medical Imaging AI (OTCQX:PYNKF) will release its first quarter 2026 financial and operating results after market close on Thursday, May 28, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Perimeter Medical Imaging AI (OTCQX:PYNKF) will release its first quarter 2026 financial and operating results after market close on Thursday, May 28, 2026. Management will host a webcast and conference call at 5:00 p.m. Eastern Time to discuss results and provide a corporate update.
The call will be accessible via dial-in numbers for North America and international participants and will also be broadcast live and archived on the company’s website for later listening.
Details
News Market Reaction – PYNKF
On May 22, the first trading day after this news, PYNKF closed 15.05% above the previous close.
Data tracked by StockTitan Argus for the May 22 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
First Quarter Results Conference Call Details:
Date: | Thursday, May 28, 2026 |
Time: | 5:00 pm Eastern Time |
Dial-In Numbers: | 1-800-717-1738 ( |
The call will also be broadcast live and archived on the Company's website here.
About Perimeter Medical Imaging AI, Inc.
Based in
Indications for Use: The Claire OCT System is an adjunctive three-dimensional imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer-aided detection algorithm which identifies and marks focal areas suspicious for breast cancer. It is used concurrently with physician interpretation of the images. The Claire OCT System is intended for use in conjunction with other standard methods for evaluation of the margins of excised lumpectomy tissue during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer.
The Claire OCT System should not be used to replace standard tissue histopathology assessment and should not be used for diagnosis. The device is not intended for use in any of the following individuals: under the age of 18, male, have metastatic cancer (Stage IV), have lobular carcinoma as their primary diagnosis, have had previous ipsilateral breast surgery for benign or malignant disease within two years (including implants and breast augmentation), patients with multi-centric disease (histologically diagnosed cancer in two different quadrants of the breast), unless resected in a single specimen, patients with bilateral disease (diagnosed cancer in both breasts), patients who are currently lactating, patients who are currently pregnant, or concurrent use in surgeries with cryo-assisted localization. Refer to prescriber labeling for full safety information.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CONTACTS:
Stephen Kilmer
Investor Relations
Direct: 647-872-4849
Email: skilmer@perimetermed.com
Adrian Mendes
Chief Executive Officer
Toll-free: 888-988-7465 (PINK)
Email: investors@perimetermed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/perimeter-schedules-first-quarter-2026-financial-results-conference-call-for-may-28th-302779422.html
SOURCE Perimeter Medical Imaging AI Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.